Lanerkitug Biosimilar - Research Grade

Human

CCR8

>1mg/ml

IgG1 - lambda2

CHO Cells

Azirkitug Biosimilar - Research Grade (ICH5368), Cafelkibart Biosimilar - Research Grade (ICH5420), Denikitug Biosimilar - Research Grade (ICH5474)

https://www.imgt.org/mAb-DB/

ICH3002

P51685

1237

Blue ice

This product (ICH5625) is an unconjugated, non-therapeutic recombinant analog of the anti-CCR8 antibody lanerkitug, produced as a research-grade reagent for laboratory use only. It reproduces the human IgG1/lambda framework and target specificity of the originator molecule so that scientists can study CCR8 engagement in a controlled setting, without using clinical drug material. It is supplied for functional and biochemical research: as a positive control or benchmarking tool alongside in-house anti-CCR8 candidates, for binding and epitope-competition assays, for developing and validating detection or ADCC/ADC workflows, and for preclinical in-vitro characterization. The reagent is offered at low endotoxin (research grade typically under 1 EU/mg, with ultra-low-endotoxin under 0.5 EU/mg options) and in bulk milligram-to-gram quantities to support screening campaigns, assay standardization, and scale-dependent studies. It is not the clinical therapeutic and is not intended for human or veterinary use, diagnosis, or treatment. Researchers should confirm suitability, format, and lot-specific specifications for their particular application before use. CCR8 (C-C chemokine receptor type 8; UniProt P51685) is a seven-transmembrane G protein-coupled receptor whose principal ligand is the chemokine CCL1 (I-309); engagement drives Gi-coupled signaling and chemotactic and survival responses. CCR8 is expressed on subsets of T cells, notably a fraction of skin-homing and Th2 cells, and is characteristically enriched on tumor-infiltrating regulatory T cells (Tregs). Because CCR8 marks highly suppressive intratumoral Tregs while being low on peripheral blood and most normal tissues, it has attracted strong interest as a tumor-selective immuno-oncology target: depleting or modulating these Tregs is hypothesized to relieve local immune suppression. CCR8 also contributes to Th2-type inflammation and tissue-resident memory T-cell biology, making it relevant to both oncology and immunology research.

CC-CKR-8, CCR-8, CDw198, CKRL1, CMKBR8, CMKBRL2, CY6, GPRCY6, TER1, C-C motif chemokine receptor 8

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Lanerkitug (anti-CCR8) Biosimilar

Q: Is the Lanerkitug biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lanerkitug biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lanerkitug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lanerkitug that binds CCR8; for research use only.